GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Net Change in Cash

Stella Diagnostics (Stella Diagnostics) Net Change in Cash : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Stella Diagnostics's Net Change in Cash for the three months ended in Sep. 2023 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Stella Diagnostics Net Change in Cash Historical Data

The historical data trend for Stella Diagnostics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Net Change in Cash Chart

Stella Diagnostics Annual Data
Trend
Net Change in Cash

Stella Diagnostics Quarterly Data
Sep22 Sep23
Net Change in Cash - -

Stella Diagnostics Net Change in Cash Calculation

Stella Diagnostics's Net Change in Cash for the fiscal year that ended in . 20 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=+++
=0.00

Stella Diagnostics's Net Change in Cash for the quarter that ended in Sep. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0+0+0+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Diagnostics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Net Change in Cash
Comparable Companies
Traded in Other Exchanges
N/A
Address
50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104
Website
https://www.stelladx.com
Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.

Stella Diagnostics (Stella Diagnostics) Headlines

From GuruFocus

Stella Diagnostics Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting

By GuruFocusNews GuruFocusNews • 04-06-2022

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

By GuruFocusNews GuruFocusNews • 06-10-2022

Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com

By GuruFocusNews GuruFocusNews • 02-15-2022

Stella Diagnostics Named 'Best Clinical Proteomics Solution' of 2021 by Biotech Breakthrough Awards

By GuruFocusNews GuruFocusNews • 02-16-2022

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

By GuruFocusNews GuruFocusNews • 06-20-2022

Stella Diagnostics to Present at "Next Big Thing" Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting

By GuruFocusNews GuruFocusNews • 03-02-2022

Stella Diagnostics and Collaborators Publish Peer-Reviewed Article Highlighting Current Limitations and Future Innovations for Barrett's Esophagus-Related Cancer

By ACCESSWIRE ACCESSWIRE • 09-09-2021

Stella Diagnostics Announces Leadership Changes: Dr. Joe Abdo Assumes a New Role as Chief Scientific Officer, and Director David Seaburg is Appointed Chief Executive Officer

By GuruFocusNews GuruFocusNews • 04-22-2022

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

By GuruFocusNews GuruFocusNews • 07-10-2022

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

By GuruFocusNews GuruFocusNews • 05-21-2022